Scarica l'app Stockscreener
108.53
0.65%
0.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more (BCS:NYSE) - Seeking Alpha
Incyte antibody speeds platelet normalization in MF and ET trial - Stock Titan
Incyte Stock (US45337C1027): Ownership shifts and pipeline focus keep shares in view - AD HOC NEWS
Lymphoma drug combo cut risk of progression or death 25% - Stock Titan
Incyte reports positive Phase 3 trial results for lymphoma drug - Investing.com
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival - Yahoo! Finance Canada
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more - Medical Marketing and Media
Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors - AD HOC NEWS
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings - Investor's Business Daily
Incyte Corporation $INCY Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Incyte bolsters haematology portfolio in $2bn Vega buyout - msn.com
Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore! - Smartkarma
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Incyte to Acquire Vega Therapeutics from Star Therapeutics for Up to $2 Billion - Global Legal Chronicle
Why Incyte (INCY) Stock Is Up Today - Yahoo Finance
Incyte (INCY) director Jacqualyn Fouse awarded RSUs and 6,111 stock options - Stock Titan
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal - Investing.com
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - msn.com
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Yahoo Finance
INCY Maintains Rating by HC Wainwright & Co. -- Price Target Rai - GuruFocus
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte (NASDAQ:INCY - Benzinga
HC Wainwright Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Incyte to acquire blood disorder drug candidate for $2B - Delaware Business Times
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition - Investing.com
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition By Investing.com - Investing.com UK
Incyte Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Natixis Advisors LLC Purchases 10,795 Shares of Incyte Corporation $INCY - MarketBeat
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu - GuruFocus
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff - MSN
Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B - Law360
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com - Investing.com Australia
Oppenheimer raises Incyte stock price target on Vega acquisition - Investing.com
Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders - Pulse 2.0
Incyte (INCY) to Acquire Vega Therapeutics for $1.25B - GuruFocus
Incyte to acquire Vega Therapeutics in deal valued at up to $2B - The Business Journals
Incyte to acquire Star subsidiary Vega Therapeutics - The Pharma Letter
Incyte acquires Vega Therapeutics in $1.25 billion deal - grafa.com
Incyte Acquires Vega Therapeutics for $2 Billion, Expanding Hematology Portfolio with Phase 3 Bleeding Disorder Drug VGA039 - Minichart
Incyte to Acquire Vega Therapeutics in Up to $2 Billion Hematology Expansion - citybiz
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders - BioSpace
Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival - MyChesCo
Incyte makes Vega deal official, paying $1.25B upfront for bleeding disorder biotech - FirstWord Pharma
Incyte to buy company in late stages of development of bleeding control drug - Delaware Business Now
Incyte to buy blood disorder drug in possibly $2B deal - Yahoo Finance
Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset - TradingView
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary - Yahoo Finance
Savant Capital LLC Cuts Stake in Incyte Corporation $INCY - MarketBeat
BRIEF—Incyte eyeing acquisition of Star Therapeutics - The Pharma Letter
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):